Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChemET: Entecavir prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy
2008-007296-24Phase 2Completed
- Sponsor
- Lila Sciences
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entecavir in Chronic Hepatitis B (CHB), Non-hematologic malignancy and hematopoietic malignancies, sponsored by Lila Sciences. Primary endpoints: Maintenance of serum HBV-DNA suppression and Prevention of HBV reactivation-related clinical events. Started Mar 2009; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on 2008-007296-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007296-24.